What new treatment agents have revolutionized the treatment of age-related macular degeneration (AMD)?

Anti-vascular endothelial growth factor (anti-VEGF) agents have indeed revolutionized the treatment of age-related macular degeneration (AMD). These agents specifically target and inhibit VEGF, a protein that promotes the growth of abnormal blood vessels in the eye, which is a primary factor in the progression of wet AMD. By reducing the effects of VEGF, these treatments can effectively decrease fluid leakage and the formation of new, detrimental blood vessels, leading to improved visual outcomes for patients.

The introduction of anti-VEGF therapy has marked a significant advancement in the management of wet AMD, substantially improving the quality of life for patients who previously faced potential blindness. Regular injections of these agents have become standard practice, and their efficacy has been demonstrated in numerous clinical studies, solidifying their role as a cornerstone of modern ophthalmologic treatment for AMD.